A Covid-19 vaccine developed and tested in Russia generated neutralizing antibodies in dozens of study subjects, and while the vaccine often caused side effects such as fever, those side effects were mostly mild, according to data published Friday in the medical journal The Lancet.
Russia drew criticism when it announced the world’s first approved coronavirus vaccine for public use in August – even before crucial Phase 3 trials had been completed.
In the Phase 1 and 2 studies of the vaccine, which is named Sputnik V, all 76 study participants developed antibodies to the virus that causes Covid-19, according to Friday’s report in The Lancet.
The levels of neutralizing antibody response were similar to the immune response that people had after naturally recovering from Covid-19, according to the study.
A handout photo released by Russian Healthcare ministry (Minzdrav) shows containers with a newly registered vaccine against coronavirus in Moscow, Russia.
The researchers also looked at responses from T cells, another component of the immune system.
“Outcomes from the trial also suggest the vaccines also produce a T cell response within 28 days,” the researchers wrote.
Larger trials needed
Scientists not involved in the study said that, while the results are a positive sign, only larger, Phase 3 trials can confirm whether the vaccine actually prevents illness with Covid-19.
“The data on the Russian vaccine studies reported in The Lancet are encouraging,” said Brendan Wren, professor of microbial pathogenesis, London School of Hygiene and Tropical Medicine.
In the study, half of the participants developed fevers and 42% developed headaches. In addition, about 28% experienced weakness and 24% had joint pain.
The article did not say how long these side effects lasted but said “most adverse events were mild.”
The vaccine was registered in Russia in August, before it had gone through large-scale trials. The researchers at the Gamaleya National Research Centre for Epidemiology and Microbiology in Russia received approval on August 26 to do a Phase 3 trial, which is expected to have 40,000 volunteers, according to a press release from The Lancet.
The researchers are already distributing the vaccine to high-risk groups, according to Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF), which is financing Russian vaccine research.
Gamaleya is using adenoviruses in their Covid-19 vaccines; this is the same approach used in the vaccine developed by the University of Oxford and AstraZeneca. The adenovirus delivers genetic material for the spike protein that sits atop the virus that causes Covid-19, and that genetic material is designed to generate an immune response to the virus.
Adenoviruses can cause a variety of symptoms, including the common cold. The researchers manipulate the virus so it will not replicate and cause illness.
The Gamaleya vaccine is given in two doses, and each dose uses a different adenovirus vector.
“Using two different viruses gives a theoretical advantage,” said Dr. Paul Offit, a vaccinologist at the University of Pennsylvania.
Naor Bar-Zeev, deputy director of the International Vaccine Access Center at Johns Hopkins University, said in a linked comment that the studies are “encouraging but small,” according to The Lancet. Bar-Zeev was not involved in the Russian study, but peer reviewed it.
Dmitriev, CEO of the RDIF, said that the trial results confirm the “high safety and efficacy” of the vaccine, adding in a statement Friday that the results are “a powerful response to skeptics who unreasonably criticized the Russian vaccine.”
Mass trials begin next week
Russia has previously said it plans to begin mass vaccination of citizens in October, and the country’s health ministry has said the country’s frontline medical staff and teachers will be the first vaccinated.
Post-registration trials of the vaccine will begin in Moscow next week, the city’s mayor, Sergey Sobyanin, said Friday.
More than 5,000 people have already signed up to participate in the trials, according to Sobyanin, who spoke during a video conference with Russian President Vladimir Putin.
Sobyanin also announced that he had been vaccinated with the first of the vaccine’s two shots.
The mayor said polls suggest around half of Russian citizens are skeptical about the vaccine.
“According to the polls, around half doubt whether they need to get vaccinated for coronavirus, whether it is developed enough or not. Two months ago, there were almost 90% skeptics,” said Sobyanin.
Without completed Phase 3 trials, Russia has not proven to the world Sputnik V works, though Dmitriev has previously said several countries in Latin America, the Middle East and Asia have expressed interest in procuring the vaccine.
Russia isn’t the only country fast-tracking its vaccine — China approved an experimental coronavirus vaccine in June for members of its military, and in August, it emerged the country had been using the vaccine on those in “high risk” professions — such as frontline medical professionals and border inspectors — since July.
- Stephen Appiah excludes Asamoah Gyan from his list of best Ghanaian players
- 30 communities in Central and Greater Accra Regions to experience ‘dumsor’
- ‘I dread pain and abuse’ – A female head porter opens up on her daily trauma
- ‘Government is either feigning incompetence on the point of how we fix structures or is pretending to fix them’ – Barker-Vormawor
- Police arrest notorious armed robber in Tema
- Debt increase of 137% between 2016 and 2020 lower than previous administrations – Ofori-Atta
- CID probes 53 schools over alleged corruption in school feeding programme; GES directs co-operation
- Covid-19: GHS to roll out second doses from May 19
- Virologist warns of third wave of Covid-19 in Ghana
- NSMQ2021: Mfantsipim School begins redemption campaign from regional qualifiers
MMDCEs and MPs must collaborate to stimulate development – Kwadaso MP
Gov’t to roll out eight additional interventions this month under Ghana CARES programme-Ofori-Atta
#FixTheCountry: Put your concerns in a workable format so we engage – Government to protesters
Trade Minister commends Ibrahim Mahama for investing in cement industry
NSMQ2021: Get trainers for your students to do better – Northern Region Education Director to school heads
‘Culture of silence’ rumours are false; media is doing well – Oppong Nkrumah
20% of Ghana’s population have at least one form of mental illness – Mental Health Officer
Developments in Chad worrying – CFR-Ghana laments
National Association of Small Scale Miners accuses military of burning excavators owned by legal miners
NSMQ2021: Northern landlords, Tamasco, three others secure tickets for national championship
Females outnumber males in Covid-19 vaccinations – GHS research shows
#FixTheCountry: We expected government to listen instead of speak – Convener
NPP will break 8-year election jinx- Ishmael Ashitey
Covid-19 scared us from family planning treatment – Adolescents in Tema Metropolis
FORIG begins research into over 60 lesser-known timber species to reduce deforestation